Reported 1 day ago
Eli Lilly and Company saw its share price drop by 6.6% following a downgrade in its sales forecasts for the full year of 2024 and disappointing preliminary fourth-quarter results. The company's sales for its leading GLP-1 drugs, Mounjaro and Zepbound, fell short of expectations, prompting worries over declining demand. Despite the setback, Lilly anticipates revenue growth in 2025 through international expansions and increased manufacturing. The competitive landscape in the GLP-1 market continues to shift, affecting the overall stock performance of industry players.
Source: YAHOO